Superiority of anthracycline‐free treatment in standard‐risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis

Abstract

AbstractBackgroundRecent advances in the treatment of acute promyelocytic leukemia (APML) have seen unprecedented improvements in patient outcomes. However, such rapid growth in understanding often leads to uncertainty regarding superiority among candidate treatment regimens, especially when further scrutinized from an epidemiological perspective.AimsThe aim of this systematic review with epidemiological analysis was to identify and compare commonly utilized protocols for standard‐risk APML with a particular focus on complete remission (CR), overall/disease‐free survival (DFS), and reported adverse events.Methods and ResultsMedline, Scopus, and CINAHL were interrogated to identify studies utilizing all‐trans retinoic acid (ATRA) in addition to arsenic trioxide (ATO) and/or anthracyclines such as idarubicin (IDA) in the treatment of de‐novo APML. After collation of studies, an epidemiological analysis was subsequently performed to compare protocols with regards to outcomes of interest using number needed to benefit (NNB) and number needed to harm (NNH) measures.Seventeen articles, describing 12 distinct trials, were included in the analysis. These trials made use of three unique protocols; CR rates were 94%–100% for ATO/ATRA regimens, 95%–96% for ATO/ATRA/anthracycline regimens, and 89%–94% for ATRA/anthracycline regimens. Epidemiological analysis demonstrated NNB for CR was 9.09 (ATO/ATRA vs. ATRA/IDA) and 20.00 (ATO/ATRA vs. ATO/ATRA/IDA), NNH for neutropenia was −3.45 (ATO/ATRA vs. ATRA/IDA), and NNH for infection was −3.13 (ATO/ATRA vs. ATRA/IDA) and −1.89 (ATO/ATRA vs. ATO/ATRA/IDA).ConclusionThe ATO/ATRA regimen is superior to chemotherapy‐containing protocols at inducing remission and promoting survival in patients with APML. The regimen is better tolerated than the proposed alternatives with fewer adverse events. Future research opportunities include quantifying APML epidemiology and pursuing oral arsenic as an option for simplification of therapeutic protocols.